FACS dataset supporting paper "A preclinical randomized controlled multicenter trial of anti-IL-17A treatment for acute ischemic stroke"

This folder contains the raw fcs files and TTC stainings, used for the study "A preclinical randomized controlled multicenter trial of anti-IL-17A treatment for acute ischemic stroke". See related materials in Collection at: https://doi.org/10.25452/figshare.plus.c.6371439 Manuscript abstract Multiple consensus statements have called for preclinical randomized controlled trials (pRCT) to improve translation in stroke research. We investigated the efficacy of an IL-17A neutralizing antibody in a multicenter pRCT using a murine ischemia reperfusion stroke model. Twelve week old, male C57BL/6 mice were subjected to 45 minutes of transient middle cerebral artery occlusion (tMCAO) in four centers. Mice were randomly assigned (1:1) to receive either an anti-IL-17A (500 µg) or isotype antibody (500 µg) intravenously one hour after reperfusion. The primary endpoint was infarct volume measured by MRI three days after tMCAO. Secondary analysis included mortality, neurological score, neutrophil infiltration and the impact of the gut microbiome on treatment effects. Out of 136 mice, 109 mice were included in the analysis of the primary endpoint. Mixed model analysis revealed that IL-17A neutralization significantly reduced infarct sizes (anti-IL-17A: 61.77 ± 31.04 mm3; IgG control: 75.66 ± 34.79 mm3; p=0.01). Secondary outcome measures showed a decrease in mortality (Hazard Ratio=3.43, 95% CI=1.157-10.18; p=0.04) and neutrophil invasion into ischemic cortices (anti-IL-17A: 7222 ± 6108 cells; IgG control: 28153 ± 23206 cells; p

本文件夹包含用于"抗IL-17A治疗急性缺血性脑卒中的临床前随机对照多中心试验"研究的原始FCS（Flow Cytometry Standard）文件与TTC（Triphenyltetrazolium Chloride）染色样本。相关实验材料可参见下述馆藏：https://doi.org/10.25452/figshare.plus.c.6371439

论文摘要
多项共识声明均呼吁开展临床前随机对照试验（pRCT），以改善脑卒中研究的成果转化。本研究采用小鼠脑缺血再灌注卒中模型，在多中心临床前随机对照试验（pRCT）中评估IL-17A中和抗体的治疗效果。来自四家中心的12周龄雄性C57BL/6小鼠接受了45分钟的短暂性大脑中动脉阻塞（tMCAO）造模。造模后1小时，小鼠按1:1比例随机分组，经静脉注射抗IL-17A抗体（500 μg）或同型对照抗体（500 μg）。本研究的主要终点为tMCAO造模后3天通过磁共振成像（MRI）测得的脑梗死体积。次要分析内容包括死亡率、神经功能评分、中性粒细胞浸润情况，以及肠道菌群对治疗效果的影响。在136只小鼠中，共109只被纳入主要终点分析。混合效应模型分析结果显示，IL-17A中和可显著缩小脑梗死体积（抗IL-17A组：61.77±31.04 mm³；IgG对照组：75.66±34.79 mm³；p=0.01）。次要结局指标显示，小鼠死亡率有所降低（风险比=3.43，95%置信区间=1.157-10.18；p=0.04），且缺血皮层的中性粒细胞浸润量减少（抗IL-17A组：7222±6108个细胞；IgG对照组：28153±23206个细胞；p